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Abstract Many proteases are produced as zymogens bearing an
N-terminal proregion acting both as intramolecular chaperone
and as enzyme inhibitor. We studied here the inhibition
mechanism of the yeast proprotein convertase Kex2p by its
proregion. A recombinant secreted and soluble form of Kex2p
was produced in Pichia pastoris and its enzymatic properties
toward a fluorogenic synthetic peptide were characterized.
Recombinant Escherichia coli-produced Kex2p proregion speci-
fically and potently inhibited the enzyme, with an IC50 of 160
nM. Exploration of the inhibition mechanism revealed that the
proregion behaved as a mixed inhibitor. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
All known proteases are synthesized as inactive precursors
(or zymogens) which are converted into active enzymes within
a speci¢c subcellular compartment or in the extracellular mi-
lieu [1]. By this mechanism, early action of the enzymes is
prevented and proteolytic activities are con¢ned to the com-
partment where their function is required. In many cases,
activation occurs by removal of an inhibitory segment usually
located in the N-terminus of the protein [1^3].
In the eukaryotic secretory pathway, a group of serine pro-
teases, known as the kexin/subtilisin-like prohormone conver-
tases (PCs), are involved in the maturation of hormones and
secreted peptides at pairs of basic residues [4,5]. These pro-
teases belong to the subtilase superfamily and share high ho-
mology with bacterial subtilisin [6]. PCs are synthesized as
precursors, bearing a 83^106 amino acid long proregion which
is cleaved in an autocatalytic manner soon after completion of
the enzyme biosynthesis in the cell endoplasmic reticulum
(ER).
By analogy with bacterial subtilisin, two functions have
been proposed for PC proregions. First, work on furin [7,8],
Kex2p [9], and PC2 [10] showed that their proregion is essen-
tial for enzyme activity and transport out of the ER, strongly
suggesting that it may help folding of the protein, acting as
intramolecular chaperones. Second, the observation that the
furin proregion remains associated with the protease domain
through transport in the secretory pathway, and is released
only in late compartments where calcium and pH conditions
are favorable, suggested that it could act as an inhibitor [11].
This hypothesis is further supported by in vitro studies with
puri¢ed proregions and enzymes [10,12,13].
The ¢rst identi¢ed member of the PC family was the Sac-
charomyces cerevisiae Kex2p endoprotease. Kex2p is a type I
integral membrane protein located in the yeast late Golgi
compartment. The enzyme is involved in processing the K-
mating pheromone and killer toxin precursors by limited pro-
teolysis at pairs of basic amino acid residues [14,15]. Kex2p is
¢rst synthesized with an 86 amino acid long proregion at its
N-terminus that is essential for enzyme biosynthesis and ac-
tivity [16]. To further explore proregion function, we tested its
ability to act in vitro as an inhibitor of Kex2p. A secreted and
soluble form of Kex2p, ssKex2p, and Kex2p proregion were
produced by expression in Pichia pastoris and Escherichia coli,
respectively. Kinetic analysis revealed that the Kex2p prore-
gion acts as a mixed inhibitor.
2. Materials and methods
2.1. DNA manipulations and plasmid constructions
DNA manipulations were performed using standard procedures
[17,18]. Plasmid pPIC3-ssKex2p for expression of ssKex2p in P. pas-
toris was constructed by ¢rst cloning a 2 kb DNA fragment contain-
ing the ¢rst 673 codons of Kex2 from Kex2HA-pVT [9] into BamHI-
AvrII digested pPIC3 (Invitrogen, Carlsbad, CA, USA). Second, self-
annealed 5P-CTA GGA ACG CGT TC-3P oligonucleotide was in-
serted into the AvrII site of the obtained plasmid, introducing a
unique MluI site (in bold). Finally, as previously described [9], two
annealed oligonucleotides containing two hemagglutinin (HA) epitope
coding sequences were inserted into the MluI site. The structure of the
encoded protein is shown in Fig. 1A.
To construct a vector for production of proregions in E. coli, we
¢rst modi¢ed plasmid pGEX4-T3 (Amersham Pharmacia Biotech,
Uppsala, Sweden) by ligating annealed oligonucleotide 5P-AAT TTG
GCG CGC CA-3P into the EcoRI restriction site. This manipulation
introduced a unique AscI site (in bold) and destroyed the EcoRI site.
Correct sequence of the modi¢ed plasmid, called pGL55, and conser-
vation of the reading frame were con¢rmed by DNA sequencing.
Next, DNA sequences encoding full-length, N- and C-terminal frag-
ments of Kex2p proregion were excised from plasmid pAPR2 [9] and
pAPR2-derived constructs as MluI-XhoI fragments and subcloned
into pGL55 digested by AscI and XhoI.
2.2. Production of Kex2p in P. pastoris
Electroporation of the P. pastoris GS115 strain and selection of
positive clones were performed according to the supplier’s instructions
(Invitrogen). Positive cells (JGP1 strain) were cultured for 3 days at
30‡C in 100 ml BMGY as recommended by the supplier, and har-
vested by centrifugation at 1500Ug for 10 min at 4‡C. The cell pellet
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was resuspended in 25 ml BMMY containing 0.5% methanol, and
cultured for 1 day. Medium was then collected, passed through a
0.22 Wm ¢lter, and complemented with sodium azide to 10 mM and
glycerol to 40% v/v. In these conditions, culture media could be stored
for at least 2 months at 320‡C without detectable loss of Kex2p
activity. Integrity of the produced protein was con¢rmed by N-termi-
nal protein sequencing (performed at the Eastern Quebec Proteomics
Core Facility, Sainte-Foy, QC, Canada) and immunoblotting using an
anti-HA antibody.
2.3. Production of Kex2p proregion and its N- and C-terminal
fragments in E. coli
Plasmids encoding glutathione S-transferase fused to either the
Kex2p proregion, or the N-terminal (lacking the last 29 residues)
and C-terminal (lacking the ¢rst 30 residues) proregion fragments
were introduced in E. coli XL1-Blue (Stratagene, La Jolla, CA,
USA). Induction of fusion proteins by isopropyl-1-thio-L-D-galacto-
pyranoside, binding to glutathione-Sepharose beads and cleavage with
thrombin (0.05 U/Wl) were performed according to the supplier’s in-
structions (Amersham Pharmacia Biotech, Uppsala, Sweden). The
Kex2p proregion and its fragments were characterized by SDS^
PAGE. Typically, 500 ml of bacterial culture yielded about 2.5^5
mg puri¢ed protein.
2.4. Enzymatic assay for Kex2p activity
Assays (100 Wl ¢nal volume) were performed in 50 mM Tris^acetate
pH 7.0 and 2 mM CaCl2. Substrate (pERTKR-methylcoumarinamide
(MCA), Peptide international, Louisville, KY, USA) stock solution in
dimethyl sulfoxide was diluted to ¢nal concentrations of 10^100 WM.
Reaction was initiated by adding 2 Wl enzyme (culture supernatant as
prepared above) diluted to 9.6 Wg/ml in reaction bu¡er. For inhibition
assays, proregion at a concentration of 100 WM in phosphate-bu¡ered
saline, or N- and C-terminal fragments at a concentration of 50 WM in
phosphate-bu¡ered saline were diluted in assay bu¡er to ¢nal concen-
trations indicated in the ¢gure legends. Readings were performed for
10 min at room temperature in a Perkin-Elmer HTS 7000 plate reader
with 360 nm and 465 nm excitation and emission ¢lters, respectively.
A standard curve from 0 to 100 WM 7-amino-4-methylcoumarin
(AMC, Sigma) allowed conversion of £uorescence units in concentra-
tion of AMC released. Reaction rates were determined by linear re-
gression and expressed in concentration of AMC released in WM per
hour. Data were collected in duplicate and each value is the mean of
at least three independent experiments.
3. Results and discussion
3.1. Yeast P. pastoris synthesizes a correctly processed
active ssKex2p
A P. pastoris strain expressing ssKex2p (Fig. 1A) was con-
structed (see Section 2) and named JGP1. Culture medium
from strain JGP1 was analyzed by SDS^PAGE and Coomas-
sie brilliant blue staining. A single protein of approximately
80 kDa was detected after induction of the culture with 0.5%
methanol for 24 h (Fig. 1B, lane 1). Typically, 100 mg of
protein per liter of culture was obtained. In the same condi-
tions, no protein was detectable in culture of the control
GS115 strain (Fig. 1B, lane 2). The identity of the secreted
protein was con¢rmed by N-terminal sequencing. The amino
acid sequence obtained (underlined in Fig. 1A) corresponds to
the mature Kex2p sequence expected after autocatalytic re-
moval of the proregion and N-terminal processing by the
dipeptidyl aminopeptidase Ste13p [19]. In addition, immuno-
blotting using anti-HA antibodies con¢rmed the presence of
the HA epitope in the C-terminus of ssKex2p (data not
shown). It thus appears that the yeast P. pastoris can correctly
process Kex2p zymogen.
Enzymatic assays were performed using the £uorogenic
peptide pERTKR-MCA. Supernatant of control GS115 cul-
ture did not release detectable AMC £uorescence, indicating
that no dibasic-speci¢c protease is secreted by this strain (Fig.
1C). In contrast, high cleavage activity was found in super-
natant of the ssKex2p-expressing strain (Fig. 1C). A KM value
of 19.1 þ 3.1 WM was determined for ssKex2p in agreement
with that previously reported (KM = 25.3 WM) for Kex2p ob-
tained by shedding from vaccinia virus-infected cells [20]. At
Fig. 1. Production of ssKex2p in P. pastoris and characterization of the enzyme. A: Schematic representation of ssKex2p. Amino acid sequence
is presented in one letter code. Closed and open arrows indicate processing of precursor by Kex2p (autocatalytic) and Ste13p, respectively. Ma-
ture ssKex2p is shown boxed, residues identi¢ed by N-terminal sequencing are underlined. C-terminal copies of the HA tag are represented by
the dotted box. B: SDS^PAGE analyses. Supernatants (5 Wl) of methanol-induced cultures of JGP1 and control GS115 strains (lanes 1 and 2,
respectively) were resolved on 8% polyacrylamide gel and stained with Coomassie brilliant blue. C: Plot of substrate hydrolysis rate against
substrate concentration. JGP1 strain: open symbols; GS115 control strain: solid symbol. KM and Vmax values were determined by non-linear
¢tting to the Michaelis^Menten equation.
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saturation of substrate, a Vmax value of 585.5 þ 29.2 WM/h was
obtained. As expected, cleavage of the synthetic peptide was
inhibited by EDTA (Fig. 2B; compare Ctrl and E) since
Kex2p is a Ca2-dependent enzyme.
3.2. The proregion of Kex2p is an inhibitor of the enzyme
The Kex2p proregion and its N- and C-terminal fragments
(Fig. 2A) were expressed in E. coli. In each case, a single
protein was eluted from the glutathione-Sepharose beads
upon thrombin cleavage and washes (results not shown).
When added to the enzymatic assay at a concentration of
1 WM, Kex2p proregion e⁄ciently inhibited cleavage of
pERTKR-MCA by ssKex2p (WT in Fig. 2B). No inhibition
was observed when 500 nM of an N-terminal (N in Fig. 2B)
or a C-terminal fragment (C in Fig. 2B) of the proregion was
added to the enzymatic assay. Addition of 625 nM of ubiq-
uitin, a 77 amino acid unrelated protein lacking any dibasic
site, had no e¡ect on enzyme activity (Fig. 2B). Furthermore,
addition of thrombin at 5U1036 U/Wl did not change the
reaction velocity (data not shown) ruling out any ssKex2p
degradation by residual thrombin activity in proregion prep-
aration. We next determined the inhibitory potency of pro-
kex2 by measuring the concentration required to inhibit 50%
of total activity (IC50). The proregion was found to be a good
inhibitor with an IC50 of 160 nM (Fig. 2C).
3.3. Kex2p proregion is a mixed-type inhibitor
To explore the inhibition mechanism of Kex2p by its pro-
Fig. 2. Inhibition of ssKex2p by recombinant Kex2p proregion. A: Amino acid sequences of recombinant proregions used in this study. The
full-length proregion (WT) is 86 residues long. The N-terminal (N) and C-terminal (C) proregion fragments encompass residues 1^57 and 31^
86, respectively. B: E¡ect of EDTA, full-length or truncated proregions, and ubiquitin on ssKex2p activity. Substrate hydrolysis rate was deter-
mined in the presence of 10 mM EDTA (E), 1 WM full-length proregion (WT), 500 nM proregion N-terminal fragment (N), 500 nM proregion
C-terminal fragment (C) or 625 nM ubiquitin (Ub) and expressed as percentage of activity of control (Ctrl). C: Determination of proregion
IC50. ssKex2p activity was measured in the presence of varying concentrations of proregion and expressed as percent of activity measured in
the absence of proregion. Assays were performed at 100 WM of substrate.
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region, assays were performed with various substrate and pro-
region concentrations (10^100 WM and 50^200 nM, respec-
tively). Fluorescence was released linearly during the experi-
ment, indicating that the steady-state binding of the proregion
to the enzyme is rapidly reached. This result suggests that the
Kex2p proregion is not a slow-binding inhibitor, unlike pro-
regions of furin, PC1 and PC7 [12,13]. Analysis of the reac-
tion initial velocities (v) as a function of substrate concentra-
tion ([S]) for each proregion concentration showed that
apparent KM and Vmax increased and decreased, respectively,
with increasing amounts of proregion (not shown). In Eadie^
Hofstee plots of v against v/[S] (Fig. 3A), both the slopes and
values of ordinates at the origin decreased with increasing
amounts of proregion. These data suggest a mixed-type inhi-
bition, in which the proregion binds the free enzyme as well as
the enzyme^substrate complex (ES). The Lineweaver^Burk
plot of 1/v against 1/[S] (Fig. 3B), in which the curves inter-
sected at a single point over the abscissa, con¢rmed the inhi-
bition mechanism and indicated that the inhibition constant
for binding to free enzyme (Ki) is superior to that (KiP) for
binding to the ES. The enzyme^inhibitor and the ES^inhibitor
complexes are likely to be inactive, since activity tends to zero
with increasing proregion concentration (Fig. 2C).
To explain this mixed-type inhibition, we postulate that
binding of the proregion, which is a 86 amino acid residue
long polypeptide, to the protease domain occurs at more than
one site. The non-competitive component of the inhibition
would result from binding of the proregion to site(s) outside
the catalytic pocket. Presence in the catalytic pocket of the
small-size substrate used in the present study would not pre-
vent binding of the proregion to these outside sites. Binding of
the proregion to the outside site(s) would alter enzyme con-
formation, resulting in a catalytically inactive complex. The
competitive component of the inhibition could result from
substrate-like positioning of the proregion C-terminus in the
catalytic site. Indeed, the autocatalytic processing of Kex2p in
vivo implies that the proregion C-terminus interacts with the
active site. Alternatively, covering of the catalytic pocket by
part of the proregion could prevent the substrate accessing the
catalytic residues. The observation that inhibition requires
integrity of both N- and C-termini of the proregion suggests
a cooperative binding to the enzyme. This model of inhibition
is strongly supported by our recent ¢ndings that several ami-
no acid residues located throughout the proregion structure
and including the C-terminal pair of basic residues are essen-
tial for proregion function in vivo and binding to the mature
protease domain in vitro (see [9] and Lesage et al., submitted).
Furin, PC1 and PC7 [12,13] proregions act as slow-binding
competitive inhibitor. To explain why Kex2p proregion be-
haves di¡erently, one can speculate that in furin, PC1 and
PC7, binding of the proregion occurs at only one site in the
catalytic pocket. Alternatively, binding to outside site(s) does
not alter the conformation of those enzymes. Further work,
including mutagenesis and structural studies, is required to
better understand molecular mechanisms involved in the pro-
region binding to their cognate enzymes, and to determine
what are the residues involved in the inhibition process.
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